UK-based cannabinoid pharmaceutical company Ananda Pharma has received ethics approval for a Phase 1 clinical study for its lead compound in Australia.
According to Prohibition Partners’ new Global Cannabis Report: 5th Edition, launching today, Australia’s medical cannabis revenues are expected to grow from around US$600m in 2024 to more than US$1.2bn by 2028.
Australia and New Zealand are undergoing contrasting reforms in their medical cannabis regulations. New Zealand aims to lower product quality
Jazz Pharmaceuticals Epidiolex (Epidyolex in the EU and UK), Jazz Pharmaceuticals’ market leading cannabis-based medication, has received authorisation to
Incannex has announced it will be relocating to Delaware, United States from Australia. A newly formed Delaware corporation called Incannex
Canada’s biggest cannabis underdog SNDL delivers transformational year Cannabis company and liquor retailer, SNDL Inc., had a record net revenue
AFTER securing market access and approvals in both Denmark, Sweden and UK, STENOCARE A/S (“Stenocare”) now takes a first and
BofC Live is the daily news and interview program of Business of Cannabis. Business of Cannabis highlights the companies, brands,
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
